through glycan engineering.
Our mission
The next generation of therapeutics.
Kyron.bio unlocks superior protein therapeutics by harnessing the power of glycan modifications.
Our novel engineering strategy precisely controls glycosylation patterns, opening a new era of antibody therapeutics.
This has the power to deliver better therapies and transform patient outcomes.
Our people
are dedicated to revolutionising the way we make therapeutic drugs
TEAM
ADVISORS
Marine Daou
FOUNDER'S ASSOCIATE
MEng Imperial College London
Dr. Caroline Desmurget
RESEARCH ASSOCIATE
PhD Merck Switzerland
Sabine Da Silva
EXECUTIVE ASSISTANT
BA West Chester University Pennsylvania
Dr. Emilia McLaughlin
CEO & FOUNDER
PhD Institut Pasteur Paris
Women in Leadership (EIC)
Dr. Marina Lochhead
R&D LEAD
PostDoc Institut Curie Paris
PhD Queen's University Canada
Dr. Damien Toullec
LAB MANAGER & TECHNICIAN
PhD CNRS-CRBM Montpellier
Prof. Michael Ferguson
HEAD DRUG DISCOVERY UNIVERSITY OF DUNDEE
Bjørn Voldborg
HEAD NATIONAL BIOLOGICS DTU
Dr. René Labatut
VP SANOFI
Marie Moores
INDUSTRY ADVISOR
Proudly supported by
We would love to hear from you
and leading angel investors.
News
Kyron.bio is proud to share that our CEO has been selected as a Women in Leadership Program by the European Innovation Council (EIC). This exceptional opportunity provides access to world-class mentorship, strategic leadership coaching, and a strong network of industry professionals, reinforcing our commitment to innovation and empowering women in leadership.
Kyron.bio selected for EIC Woman in Leadership Programme
2024
Kyron.bio gets selected for CDL program
Kyron.bio is proud to be one of the 20 startups selected for the Creative Destruction Lab (CDL) program. CDL is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- companies. Each year, the Berlin program selects 20 of the best Health companies in Europe providing access to top mentors such as the Managing Director of BioNTech & Global Head of Strategic Partnerships, Novartis.
2024
Caroline Desmurget joins the team as Cell Line Engineer
Caroline Desmurget has joined the kyron.bio team! Caroline has seven years of experience at Merck, where she has honed her expertise in cell line development and the optimisation of therapeutic production. Caroline will be taking care of the health and productivity of our cell lines as we continue to scale our bioproduction capabilities in house.
2024
Kyron.bio wins the Servier Spartners Golden Ticket
Kyron.bio is honoured to be the recipient of the first Golden Ticket from Servier & Spartners BioLabs, providing a year of free lab space on the Servier site and access to key mentorship from the Servier team. We are delighted to be growing our company with the support of one of the most influential players in the French ecosystem!
2024
Women TechEU is a competitive initiative funded by the European Commission designed to support female-led European deeptech startups. As a laureate, kyron.bio was awarded €75K to develop its innovative cell line engineering approach and the program provides a strong network of inspiring female leaders.
Kyron.bio selected for the Women Tech EU grant
2023